September 11th 2024
This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
BLU-667 Shows Clinical Benefit in Advanced, RET-Altered Solid Tumors
April 20th 2018BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.
Treatment Informed by PET Imaging Linked to Better Response Rates in Esophageal Cancer
January 18th 2017Patients with esophogeal cancers who received induction chemotherapy, followed by PET imaging to determine whether alternative chemotherapy was needed had improved pathologic complete response rates
Complete Responses With Reduced-Dose Radiation in HPV-Linked Oropharynx Cancers
January 10th 2017For patients with HPV-related oropharyngeal squamous cell carcinoma, induction chemotherapy plus reduced-dose radiation and weekly cetuximab brought improvements for swallowing and nutritional status along with complete clinical responses.
Oral HPV Test Shows Potential for Predicting Oropharyngeal Cancer Risk
January 30th 2016Individuals with detectable human papillomavirus (HPV)-16 in their mouthwash samples were 22 times more likely to develop oropharyngeal cancer (OPC) than those without the type of virus, according to findings of a new study.
Swallowing Exercises Help to Preserve Function in Head and Neck Cancer Patients Receiving Radiation
January 9th 2014Head and neck cancer patients who participated in a swallow preservation protocol (SPP) were less likely to suffer from the detrimental effects associated with dysphagia, a common complication associated with radiation therapy (RT) and chemoradiation therapy (CRT).